3-O-Sulfogalactosylceramide (d18:1/22:0)

Metabolite details

Identifier

UAKYQMHTPLVMJD-GJOJTGTQSA-N

InChI Key

UAKYQMHTPLVMJD-GJOJTGTQSA-N

IUPAC name

[(2R,5S,6R)-2-[(E,2S,3R)-2-(docosanoylamino)-3-hydroxyoctadec-4-enoxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] hydrogen sulate

Preferred name

3-O-Sulfogalactosylceramide (d18:1/22:0)

INN name

—

Synonym

—

ChEBI

CHEBI:176327

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Hfq Regulates Efflux Pump Expression and Purine Metabolic Pathway to Increase the Trimethoprim Resistance in Aeromonas veronii
• Metabolic Dynamics of In Vitro CD8+ T Cell Activation.
• Global analysis of plasma lipidomics reveals altered lipid signatures in patients with osteonecrosis of the femoral head
• High complexity and diel dynamics of planktonic microbiome revealed by multi-omics in Taihu, China
• Transcriptomic dynamics control rapid transition of core crop functions in 'lactating' pigeon
• Transcriptomic and lipidomic profiling of subcutaneous and visceral adipose tissues in 15 vertebrates
• TGF-β uncouples glycolysis and inflammation in macrophages and controls the survival during sepsis

Observed in differential profiles

• Wild_type_vs_hfq
• Wild_type_vs_hfq
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• Control_vs_AONFH_Stage_III_IV
• 2:00 AM_Membrane_vs_2:00 AM_Net
• Male_19_days_vs_Male_1_day
• G1_Sheep_ASA_SAT_vs_G2_Sheep_GOM_VAT
• Control_vs_TGF-beta_Treatment